

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of

Application Number

08-089407

Filed

Jul 8, 93

Art Unit

1600

Examiner

Paper No. _____

Assistant Commissioner for Patents
Washington, DC 20231

1. ☐ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☐ (A) referred to in:United States Patent Application Publication No. 67013432, page _____, line _____,

United States Patent Number _____, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Farhana Shoaib

Signature

5/08/03

Date

FARHANA SHOAIB

Typed or printed name

FOR PTO USE ONLY

Approved by: _____

(initials)

Unit: _____



US006013432A

United States Patent [19]

Luciw et al.

[11] Patent Number: 6,013,432

[45] Date of Patent: Jan. 11, 2000

[54] IMMUNOASSAY OF HIV ANTIBODIES USING RECOMBINANT OR SYNTHETIC SELECTED POL SEQUENCE

86/06414 11/1986 WIPO.

OTHER PUBLICATIONS

[75] Inventors: Paul A. Luciw, Davis; Dino Dinn, San Francisco, both of Calif.

[73] Assignee: Chiron Corporation, Emeryville, Calif.

[21] Appl. No.: 08/443,434

[22] Filed: May 17, 1995

Related U.S. Application Data

[62] Division of application No. 08/089,407, Jul. 8, 1993, which is a continuation of application No. 07/931,154, Aug. 17, 1992, which is a continuation of application No. 07/138,894, Dec. 24, 1987, Pat. No. 5,156,949, which is a continuation-in-part of application No. 06/773,447, Sep. 6, 1985, abandoned, which is a continuation-in-part of application No. 06/696,534, Jan. 30, 1985, abandoned, which is a continuation-in-part of application No. 06/667,501, Oct. 31, 1984, abandoned.

[51] Int. Cl.⁷ C12Q 1/70; G01N 33/53;
G01N 33/569; C12N 15/48

[52] U.S. Cl. 435/5; 435/7.1; 435/7.92;
435/69.3; 435/287.1; 435/320.1; 435/960;
435/974; 530/300; 530/810; 530/806; 530/826;
536/23.2

[58] Field of Search 435/320.1, 5, 7.1,
435/69.3, 7.92, 287.1, 960, 974; 530/300,
810, 826, 806; 536/23.2

[56] References Cited

U.S. PATENT DOCUMENTS

4,420,113 12/1983 Gallo .
4,708,818 11/1987 Montagnier .
4,716,102 12/1987 Levy .
5,075,211 12/1991 Cosand 435/5

FOREIGN PATENT DOCUMENTS

0 020 251 12/1980 European Pat. Off. .
0 060 057 9/1982 European Pat. Off. .
0 062 574 10/1982 European Pat. Off. .
0 073 635 3/1983 European Pat. Off. .
0 088 632 9/1983 European Pat. Off. .
0 116 201 8/1984 European Pat. Off. .
0 136 798 4/1985 European Pat. Off. .
0 138 667 4/1985 European Pat. Off. .
0 139 216 5/1985 European Pat. Off. .
0 152 030 8/1985 European Pat. Off. .
0 165 120 12/1985 European Pat. Off. .
0 173 529 3/1986 European Pat. Off. .
0 178 978 4/1986 European Pat. Off. .
0 181 150 5/1986 European Pat. Off. .
0 185 444 6/1986 European Pat. Off. .
0 187 041 7/1986 European Pat. Off. .
0 201 540 11/1986 European Pat. Off. .
0 178 978 2/1992 European Pat. Off. .
2104902 3/1983 United Kingdom .
84/23659 9/1984 WIPO .
84/16013 10/1984 WIPO .
84/29099 11/1984 WIPO .
85/01473 1/1985 WIPO .
85/04897 11/1985 WIPO .

Allan et al., *Science* (1985) 228:1091-1094.
Amann et al., *Gene* (1983) 25:167-178.
Barin et al., *Science* (1985) 228:1094-1096.
Beardsley et al., *Nature* (1984) 311:195.
Bolivar et al., *Gene* (1977) 2:95-113.
Brin-Vozinet et al., *Lancet* (1984) 1253-1256.
Casadaban et al., *J. Bacteriology* (1980) 143(2):971-980.
Chanda et al., *FASEB Proceedings* (1985) 44(5):1540.
Chang et al., *J. Cell. Biochem.* (1985) 9A: 81 Abstract 0187.
Chang et al., *Science* (1985) 228:93-96.
Chang et al., *Nature* (1985) 315:151-154.
Chang et al., *Bio/Technology* (1985) 3(10):905-909.
Chemical and Engineering News, (1984) p. 7.
Chen et al., *Nature* (1984) 309:276-279.
Chen et al., *Nature* (1983) 305:502-505.
Chermann et al., in Gottlieb et al. (eds. 1984) "Acquired Immune Deficiency Syndrome" UCLA Symposia on Molecular Biology, News Series, vol. 16 (1984) pp. 31-46.
Clinica, *Abstract* (1984) p. 9.
De Boer et al., *Proc. Natl. Acad. Sci.* (1983) 80:21-25.
DiMaio et al., *Proc. Natl. Acad. Sci.* (1982) 79:4030-4032.
Dinn et al., *DNA* (1985) 4(1):56.
Ellrodt et al., *Lancet* (1984) 1:1383-1385.
Fisher et al., *Nature* (1985) 316:262-265.
Fischinger et al., *Cancer Research* (1985) 45:4694-4699s.
French, T.J., *First Declaration of T.J. French* (1994).
Gallo et al., in Gottlieb et al. Eds. (1984) pp. 47-58
"Acquired Immune Deficiency Syndrome" UCLA Symposia on Molecular Biology, New Series (1984) 16:47-58.
Gluzman et al., *Cell* (1981) 23:175-182.
Gnan et al., *J. Virology* (1987) 61(8):2639-2641.
Gray et al., *Proc. Natl. Acad. Sci.* (1982) 79:6598-6602.
Groopman et al., *New Eng. J. Med.* (1984) 311(22):1419-1422.
Hahn et al., *Nature* (1984) 312:166-169.
Hattori et al., *Virology* (1984) 136:338-347.
Huang et al., *DNA* (1985) 4(1):70.
Kara et al., *Meth. Enzymology* (1983) 101:3-19.
Kitchen et al., *Nature* (1984) 312:367-369.

(List continued on next page.)

Primary Examiner—Michael P. Woodward
Assistant Examiner—Mary K Zeman
Attorney, Agent, or Firm—Dale H. Hoscheit, Alisa A. Harbin, Robert P. Blackburn

[57] ABSTRACT

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.